Alpha TAU Medical (“ATM”) focuses on research, development, and commercialization of Diffusing Alpha-Emitters Radiation Therapy (“Alpha DaRT”), a new type of brachytherapy for the treatment of solid tumors.
The underlying technology of the company was developed by Profs. Kelson and Keisari from Tel-Aviv University.
By using Alpha radiation rather than the commonly used Beta or Gamma radiation, ATM’s therapy achieves greater cell death with less radiation, less adverse effects and toxicities, and can be used on various types of solid tumors.
The funding round led by Shavit Capital will be used for clinical trials worldwide, as well as establish global production facilities for the radioactive DaRT seeds to meet local distribution demand.